Chinese companies dominate global gene therapy competition with 48 programs vs 20 in US, targeting expensive Western treatments like Zynteglo, Elevidys, and Roctavian at fraction of cost. More evidence that China is moving up the spectrum of innovative science.
Gene therapies were supposed to be competition-proof. They are scientifically complex, require bespoke manufacturing, often go after small patient populations and can cost millions per …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms,…
China is becoming a leader in biotech innovation. That offers hope to rare disease patients and presents a problem to American…
‘If we’re not careful, every drug could be made in China,’ warned former head of US Food and Drug Administration in May.
Bristol Myers’ alliance with Hengrui ranks as the second-largest licensing pact of its kind since the start of 2025, trailing…
Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?
After years of buying licences for foreign-made medicines, Chinese biotech firms are now profiting handsomely from their own…
